Product Usage: For Research Use Only – Not for Human or Veterinary Use

This product is not a drug, food, cosmetic, or dietary supplement and has not been evaluated by the FDA. It is strictly intended for in vitro research by qualified professionals. Any use in humans or animals is strictly prohibited and may violate federal, state, or local laws, including the Federal Food, Drug, and Cosmetic Act. No therapeutic or diagnostic application is implied or permitted. The purchaser assumes all responsibility for compliance with applicable regulations.

PT-141 research vial

PT-141 – 10mg

10mg lyophilized peptide. PT-141 (bremelanotide) is a melanocortin-receptor agonist studied in research models for its interaction with central nervous system signaling pathways. Supplied at research-grade purity for laboratory use only.

$150.00

Researchers who buy PT-141 (bremelanotide) research peptide are typically studying its behavior as a melanocortin-receptor agonist, specifically its activity at the MC3R and MC4R receptor subtypes expressed in the hypothalamus. PT-141 is one of the few compounds in this catalog with a completed FDA-approval pathway for a specific pharmaceutical formulation. The summary below reflects the published preclinical and clinical literature and is provided strictly for research and educational reference — it does not describe an intended effect of this product in humans or animals.

Buy PT-141 (bremelanotide) research peptide 10mg vial by First Class Science

In this reference:

What Is PT-141 (Bremelanotide)?

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analog derived from the melanocortin peptide alpha-MSH. Unlike most compounds in this catalog, bremelanotide has completed the full FDA drug-approval pathway: it is the active ingredient in Vyleesi, an FDA-approved on-demand subcutaneous-injection treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, approved in June 2019.

Researchers should understand this distinction clearly: the research-grade PT-141 sold on this page is a separate, unformulated research compound, not the approved Vyleesi product, its auto-injector delivery device, or its specific prescribing regimen. This page describes the published pharmacology and clinical-trial literature on bremelanotide as a molecule, for research and educational reference — it does not describe an intended use, effect, or benefit of this research-use-only product for any person.

Proposed Mechanism of Action

Published pharmacology describes bremelanotide as a non-selective agonist of melanocortin receptors, with primary reported activity at MC3R and MC4R subtypes expressed in the hypothalamus (Molinoff PB, et al., Ann N Y Acad Sci. 2003;994:96-102; PMID 12507838). Study authors have proposed that MC4R activation engages hypothalamic dopaminergic signaling pathways associated with sexual-motivation research models, representing a mechanism distinct from peripheral-vasculature-targeted approaches studied in other sexual-dysfunction-adjacent pharmacology.

Because MC3R and MC4R are also implicated in energy-homeostasis and appetite-regulation research, published literature has examined bremelanotide’s melanocortin-receptor activity across multiple research contexts beyond the specific approved indication, though the approved Vyleesi formulation’s clinical development program focused specifically on the HSDD indication described below.

Chemical Identity

Other Names Bremelanotide, PT-141
Molecular Formula C50H68N14O10
Molecular Weight ~1025.2 g/mol
Structure Cyclic heptapeptide
Appearance White to off-white lyophilized powder

Purity, Storage & Quality

First Class Science supplies this PT-141 research peptide vial at research-grade purity, verified by independent third-party HPLC testing and mass spectrometry. A Certificate of Analysis is available for every batch at our Certificate of Analysis page, listing the specific lot’s purity result, molecular-weight confirmation, and test date.

Store the lyophilized (freeze-dried) compound at −20°C for long-term stability. This vial must be reconstituted with bacteriostatic or sterile water before laboratory use; after reconstitution, refrigerate at 2–8°C and use within 4–6 weeks. Avoid repeated freeze-thaw cycles and prolonged exposure to light or room-temperature conditions, both of which are associated with accelerated peptide degradation in handling literature.

Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.

Preparing Solutions for Laboratory Use

Laboratories reconstituting lyophilized PT-141 for in vitro or animal-model research typically follow standard peptide-handling practice: the vial is brought to room temperature before opening, and a diluent — commonly reconstitution solution or sterile water for injection (SWFI) — is added slowly down the interior wall of the vial rather than directly onto the lyophilized material, to reduce foaming and mechanical stress on the peptide. The vial is then gently swirled, never shaken, until the powder is fully dissolved.

Stock-solution concentration for a given protocol is calculated by dividing the total peptide mass in the vial by the volume of diluent added, and that calculation should be recorded in the study’s protocol documentation. This page describes general laboratory reconstitution practice for research use and is not a dosing guide for human or animal administration.

Quality Control Methodology

Each production batch of this PT-141 research peptide undergoes independent third-party testing before release. High-performance liquid chromatography (HPLC) confirms purity by measuring the proportion of the target peptide relative to synthesis by-products or degradation fragments. Mass spectrometry separately confirms molecular identity, verifying that the measured mass of the material matches the expected ~1025.2 g/mol molecular weight of bremelanotide. Both results are recorded on the batch’s published Certificate of Analysis, letting researchers independently verify identity and purity rather than relying on manufacturer claims alone.

Who Should Buy PT-141 Research Peptide

Researchers who buy PT-141 from First Class Science are typically university and academic laboratories, contract research organizations (CROs), and biotechnology R&D teams running in vitro receptor-binding assays or animal-model studies on melanocortin-receptor pharmacology. First Class Science requires that all research-peptide orders be placed by parties who acknowledge and agree to the research-use-only terms stated on this page prior to purchase.

Research Applications

The published literature on bremelanotide spans several distinct research areas. Each is summarized below strictly as a description of what has been studied in animal, in vitro, or controlled clinical-trial models — not as a claim about effects for any individual using this product.

Melanocortin-Receptor Pharmacology Research

The foundational characterization work (Molinoff et al., 2003, PMID 12507838) established bremelanotide’s MC3R/MC4R agonist profile, which remains the reference point for receptor-binding and structure-activity research on this compound class.

Sexual-Desire and Hypothalamic Signaling Research (Clinical Development)

The most extensive published clinical research on bremelanotide examined its association with sexual-desire measures in a specific, defined patient population (detailed in the Human Evidence section below), as part of the completed FDA-approval program for the Vyleesi formulation.

Melanocortin-Receptor Research Beyond the Approved Indication

Because MC3R/MC4R signaling is also studied in energy-homeostasis and appetite-regulation research contexts, published pharmacology literature has examined bremelanotide’s receptor activity across these adjacent research areas, distinct from the specific HSDD indication the approved formulation was developed and studied for.

What the Human Evidence Shows

Researchers evaluating PT-141/bremelanotide should know that it has one of the most substantial completed human clinical-trial records of any compound in this catalog — because, unlike most research peptides, a pharmaceutical-grade formulation completed the full FDA drug-approval pathway. Two phase 3 randomized, double-blind, placebo-controlled trials (known as the RECONNECT studies) formed the basis of that approval; a published long-term safety and efficacy analysis reported sustained improvement in sexual-desire measures and an acceptable safety profile in premenopausal women with acquired, generalized HSDD over extended treatment (Simon JA, et al., Obstet Gynecol. 2019;134(5):909-917; PMID 30882442).

That completed clinical-trial and FDA-approval record relates specifically to the Vyleesi pharmaceutical formulation, its auto-injector delivery device, and its approved prescribing regimen for a defined patient population — it does not establish safety or efficacy for the research-grade PT-141 sold on this page, and does not support human self-administration of this research compound outside the approved product and its prescribing context. Research-grade PT-141 as supplied here is not distributed, labeled, or intended as the approved pharmaceutical product, and this specific sale is not evaluated by the FDA.

This distinction matters for how findings from this page should be characterized. A researcher citing the RECONNECT trial data in a grant application or protocol design should describe it accurately as reflecting a distinct, FDA-approved pharmaceutical formulation’s completed clinical-development record in a specific patient population, not as safety or efficacy data for the vendor-supplied research compound sold here.

PT-141 is studied within the broader melanocortin-receptor research family. First Class Science supplies related preparations for researchers running comparative studies:

Melanotan 2 – 10mg is a separately-studied, non-selective melanocortin-receptor agonist with a broader receptor profile than bremelanotide’s MC3R/MC4R selectivity, and is commonly ordered alongside PT-141 by labs running comparative melanocortin-receptor research.

Each related preparation carries its own Certificate of Analysis and is subject to the same research-use-only terms described on this page.

Common Research Study Designs

Published studies referenced throughout this page typically fall into one of three designs: in vitro melanocortin-receptor binding and pharmacology assays; and, in the case discussed above, completed phase 3 randomized controlled trials supporting a specific FDA-approved pharmaceutical formulation’s approval. Understanding which design underlies a given finding — and which product it actually describes — is important context for interpreting the strength of any individual claim in the literature.

Frequently Asked Questions

What is the purity of this PT-141 research peptide?
Every batch is independently verified via third-party HPLC and mass-spectrometry testing, with a Certificate of Analysis published for each lot.

How should PT-141 research peptide be stored?
Store the lyophilized powder at −20°C. After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks; avoid repeated freeze-thaw cycles.

Is PT-141 approved for human or animal use?
Bremelanotide, PT-141’s active molecule, is the ingredient in Vyleesi, an FDA-approved pharmaceutical formulation for a specific indication. That approval applies to the Vyleesi product only — not to the research-grade PT-141 sold on this page, which is distributed strictly for laboratory research use and is not itself an approved product.

Has PT-141 been tested in humans at all?
Yes, extensively, in the pharmaceutical-development context described above: phase 3 randomized controlled trials (the RECONNECT studies) supported the Vyleesi approval, with long-term safety and efficacy data published (PMID 30882442). This research relates to the approved formulation, not the research compound sold here.

How does PT-141 differ from Melanotan 2?
Both are melanocortin-receptor agonists. PT-141 (bremelanotide) has more selective activity at MC3R/MC4R. Melanotan 2 has a broader melanocortin-receptor activation profile. Researchers frequently study them comparatively.

What does the Certificate of Analysis show?
The Certificate of Analysis published for each batch shows the HPLC purity result, mass-spectrometry molecular-weight confirmation, lot number, and test date, allowing researchers to independently verify the identity and purity of the specific batch they receive.

Can PT-141 research peptide be shipped internationally?
Shipping availability and any import restrictions for research peptides vary by destination country and are subject to change; researchers should confirm their local import regulations for research-use-only compounds before ordering.

Shipping, Handling & Compliance

This PT-141 research peptide ships as a lyophilized powder in a sealed glass vial, packaged to maintain cold-chain integrity in transit where applicable. All orders are subject to the research-use-only terms stated on this page, and First Class Science does not sell this or any other research peptide for human or veterinary administration under any circumstance.

Order tracking, batch-specific documentation requests, and general product questions can be directed to First Class Science customer support, which can confirm current lead times and any destination-specific documentation a receiving institution may require for its own compliance records.

Disclaimer: The research summarized above is drawn from third-party published studies conducted in in vitro or controlled clinical-trial contexts. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal.

⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.